Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Bitrobius Genetics logo — Developing the Gentrafix platform technology to revolutionis...

Bitrobius Genetics

Developing the Gentrafix platform technology to revolutionise gene therapy.

Founded 2020 United Kingdom Macclesfield, United Kingdom 6 employees Series A Biotechnology, Health Care

General Information

Company Name Bitrobius Genetics
Founded Year 2020
Location United Kingdom Macclesfield, United Kingdom
Employees 6
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Bitrobius Genetics. To contact Bitrobius Genetics, visit bitrobius.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Bitrobius Genetics compare?

A PDF of Bitrobius Genetics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Bitrobius Genetics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Bitrobius Genetics

Bitrobius Genetics is a biotechnology startup, founded in 2020, with a passionate vision of utilizing the Gentrafix™ platform to revolutionize gene therapy. The company's slogan, "Developing the Gentrafix platform technology to revolutionise gene therapy," underscores its commitment to addressing a critical limitation in gene therapy: the restricted reach of therapeutic genes to affected cells in organs or tissues. By leveraging this innovative platform, Bitrobius Genetics aims to overcome this challenge, offering potential breakthroughs in the treatment of genetic diseases. Bitrobius Genetics' recent achievement includes securing a Series A investment on 01 July 2021 from Future Planet Capital, signaling a notable milestone in its journey. This backing from renowned investors reflects confidence in the company's technological advancements, affirming its potential to redefine the landscape of gene therapy. With its focus on biotechnology and healthcare, Bitrobius Genetics is poised at the forefront of innovation, holding the promise of significant impact in the field of genetic disease treatment.

Business keywords: gene therapy, DNA transfer technology, genetic diseases, cancer therapy, biomedical engineering

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 1
Future Planet Capital
Future Planet Capital
01 Jul 2021

Bitrobius Genetics Alternatives & Competitors

View All Alternatives
Bitrobius Genetics vs
Affinia Therapeutics
Affinia Therapeutics United States

Building the next generation of gene therapies

Series C
30 employees
Biotechnology, Health Care
Bitrobius Genetics vs
American Gene Technologies® International Inc.
American Gene Technologies® International Inc. United States

Our mission is to leverage the power of gene and cell therapy to reduce human suffering from serious...

Series F
26 employees
Biotechnology, Health Care
Bitrobius Genetics vs
Kelonia Therapeutics
Kelonia Therapeutics United States

Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines.

Private Equity
74 employees
Biotechnology, Health Care
View all alternatives

FAQ About Bitrobius Genetics

Developing the Gentrafix platform technology to revolutionise gene therapy.
Bitrobius Genetics was founded in 2020.
Bitrobius Genetics is headquartered in Macclesfield, United Kingdom.
Bitrobius Genetics operates in Biotechnology and Health Care. Its work centres on gene therapy, DNA transfer technology, genetic diseases and cancer therapy.
Bitrobius Genetics has approximately 6 employees.
Bitrobius Genetics has completed 1 funding round. The latest funding stage is Series A.
Top alternatives and competitors to Bitrobius Genetics include Affinia Therapeutics, American Gene Technologies® International Inc., Kelonia Therapeutics, Locanabio, Inc., AVROBIO. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bitrobius Genetics and Affinia Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bitrobius Genetics, https://bouncewatch.com/company/bitrobius-genetics, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout